Omega Funds
Venture capitalActively deployingBoston · Seed–Late Stage · 17 people tracked
Investment thesis
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Team · 17 people
from public directories
What they invest in
from 18 of 20 portfolio companiesBiotech ×13Medical Devices ×5Deep Tech ×3Healthtech ×3AI & Machine Learning ×2Advanced Manufacturing ×1Cybersecurity ×1Digital Health ×1
HQs:United States×17Colombia×1
Investments · 20 tracked
founders shown can be your intro pathHealthtechIrvine, US
Edward Damiano(Executive Officer, Director)Gilbert Clarke(Executive Officer)Edward Raskin(Executive Officer, Director)Mike Roskino(Executive Officer)Agustin Mohedas(Director)Jeff Hitchcock(Director)
Board seatFrancesco Draetta· per SEC Form D · $101.8M raise · filed Sep 2023
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
THORVALD NAGEL(Director)JASON TARDIO(Executive Officer)Tamar Howson(Director)GLENN WHALEY(Executive Officer)INDERPAL SINGH(Executive Officer)Hella Kohlhof(Executive Officer)
Board seatVincent Ossipow· per SEC Form D · $60M raise · filed Oct 2022
New York, US
Board seatMichelle DoigClaudio Nessi· per SEC Form D · $275.3M raise · filed Oct 2020
BiotechBoston, US
Mary DiBiase(Executive Officer)Murray W. Stewart(Director)Christophe Arbet-Engels(Executive Officer)David Kirske(Executive Officer)Michael S. Wyzga(Director)John Volpone(Executive Officer)
Board seatClaudio Nessi· per SEC Form D · $50.5M raise · filed May 2017
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)in
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Zachary Hornby(Chief Executive Officer)
BiotechPhiladelphia, US
Ameet Nathwani(Director)Ivan Gergel(Director)Jan Van de Bossche(Director)Carlo de Notaristefani(Director)Garrett Ingram(Director)Raj Kannan(Executive Officer, Director)
Board seatClaudio Nessi· per SEC Form D · $110.7M raise · filed Jan 2026
South San Francisco, US
Board seatOtello Stampacchia· per SEC Form D · $117M raise · filed Mar 2021
BiotechCambridge, US
Michelle Doig(Director)Aaron Royston(Director)Xiaodi Su(Director)Praveen Tipirneni(Executive Officer, Director)
BoardMichael Gladstone(Director)
Board seatMichelle Doig· per SEC Form D · $37.5M raise · filed Jan 2026
BiotechVancouver
Frank Perabo(Executive Officer)Franklin Berger(Director)Raymond Andersen(Executive Officer, Director)Scott Requadt(Director)Paul Cossum(Executive Officer)David Wood(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $36M raise · filed Aug 2019
BiotechBoston, US
Richard Wooster(Director)Jotin Marango(Executive Officer)Jean-Francois Formela(Director)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Owen Hughes(Director)
Board seatOtello Stampacchia· per SEC Form D · $75M raise · filed Jul 2025
BiotechWaltham, US
Barbara Dalton(Director)Ramy Farid(Director)Kevin Bitterman(Director)Praveen Tiprirneni(Executive Officer, Director)Timothy Springer(Director)Vikas Goyal(Director)
Board seatOtello Stampacchia· per SEC Form D · $80M raise · filed Oct 2018
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)Gary Glick(Executive Officer, Director)
Board seatOtello Stampacchia· per SEC Form D · $150M raise · filed Jul 2024
HealthtechBelleair Bluffs, US
Brian Mooney(Director)Rinda Sama(Executive Officer)
Board seatClaudio Nessi· per SEC Form D · $69.1M raise · filed Jan 2026
BiotechPalo Alto, US
Michelle Doig(Director)Idan Elmelech(Executive Officer)Pedro Beltran(Executive Officer)Frank McCormick(Director)Neil Kumar(Director)Eli Wallace(Executive Officer)
Board seatMichelle Doig· per SEC Form D · $200M raise · filed May 2024
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)
Board seatFrancesco DraettaOtello Stampacchia· per SEC Form D
XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.
Deep TechDigital HealthHealthtechMedical DevicesUnion City, US
Garrett Schwab(Chief Executive Officer)Shane Kreidel(Secretary and Chief Financial Officer)Aftab Kherani(Director)Zachary Eisen(Director)
BoardDuke Rohlen(Director)JD Friedland(Director)
Board seatSaoussen Ben Halima· per SEC Form D
GelSight develops high-resolution tactile imaging and surface metrology technology for measuring and analyzing surface properties in manufacturing.
Advanced ManufacturingAI & Machine LearningDeep TechHardware<UNKNOWN>, US
John Ho(Director)Janos Rohaly(Executive Officer)Micah K Johnson(Executive Officer, Director)
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Omega Funds invest at?
- Omega Funds invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does Omega Funds focus on?
- Omega Funds focuses on Biotech, Medical Devices.
- Where is Omega Funds located?
- Omega Funds is headquartered in Boston, US.
Media · Podcasts & interviews
featuring the team#OptimumTV meets Omega Funds Otello Stampacchia to discuss the #lifescience investor outlook on 2026
Optimum Strategic Communications · Otello Stampacchia
Extrait Conférences BIOTECH MEDTECH HEALTHTECH LeZoom19H : Vincent Ossipow, Partner chez Omega Funds
Biotech Finances · Vincent Ossipow
Co-investors · 21
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
.jpeg)
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
Norwest is a venture and growth equity investment firm that has backed over 700 companies across sectors including AI, retail, and healthcare, working alongside entrepreneurs from early to late-stage growth.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Avoro Capital Advisors is an investment firm focused on healthcare and life sciences, pursuing scientific breakthroughs that address unmet medical needs.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
.jpeg){kind=logo}
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
OUP (Osage University Partners) is a venture capital firm that backs science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
▶9 more co-investors
venBio PartnersThe Column GroupPfizer Venture InvestmentsSV Health InvestorsFrazier Healthcare PartnersHatteras Venture PartnersRoche Venture FundCofounders CapitalAgent Capital
Firms observed investing alongside Omega Funds, from public investor directories. Shared companies are the overlap with Omega Funds's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Excel Venture Management is a venture capital firm that builds and invests in companies applying life science technologies to problems in healthcare and other areas.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.